Snowflake Study: 85% of Healthcare Leaders Now Prioritize Interoperability for AI

The Budget Shift

Snowflake's March 2026 research of healthcare and public health agency leaders found 85% now treat data interoperability as a higher priority than two years ago, with interoperability explicitly named as the infrastructure requirement blocking AI deployment beyond pilots. The finding arrives as 77% of these organizations have already invested or plan to invest in generative or agentic AI technologies, creating a collision between AI ambition and data infrastructure reality.

The research identifies three primary drivers for interoperability investment: operational efficiency and decision-making (74% of respondents), improving patient experience (71%), and value-based care (64%). These percentages represent budget line items. Money previously allocated to point-to-point EHR integrations must now fund cross-platform data mobility infrastructure capable of supporting AI workloads at scale.

What This Changes for Enterprise Buyers

Healthcare IT buyers face a structural procurement decision. The traditional approach—buying interoperability as a compliance feature bundled with EHR systems or as standalone integration engines—no longer maps to organizational need. AI scaling requires data from multiple sources normalized and accessible in real time. That shifts purchasing consideration from "can this tool meet regulatory requirements" to "can this platform support our AI roadmap."

Vendors competing for this budget include Redox, Particle Health, NextGen Healthcare's Mirth Cloud Connect, traditional EHR vendors with FHIR compliance, and cloud data platforms like Snowflake. The differentiation point is no longer interoperability itself—over 90% of EHR vendors now support FHIR as baseline functionality. The question is which vendor's architecture minimizes the gap between data ingestion and AI model deployment.

Snowflake's positioning in this research is transparent: they sell an AI Data Cloud platform that bundles interoperability capabilities with AI infrastructure. Their framing of interoperability as "foundational to scaling AI" directly supports their go-to-market strategy. That does not invalidate the data, but buyers should recognize the vendor incentive structure. The claim that interoperability blocks AI scaling is consistent with buyer behavior—77% AI investment rate combined with 85% interoperability priority increase suggests organizations hit infrastructure limits during pilot-to-production transitions.

Market Size and Regulatory Context

The broader healthcare data interoperability market is projected to reach $14.98 billion by 2030 at a 14.8% CAGR, with the interoperability solutions segment specifically estimated at $8.57 billion by 2030, up from $3.4 billion in 2023. This growth reflects sustained enterprise investment driven by regulatory mandates, not optional modernization.

The 21st Century Cures Act and CMS's Interoperability Framework created non-discretionary spending requirements. The Trusted Exchange Framework and Common Agreement (TEFCA) establishes mandatory technical guardrails that make interoperability investment a compliance cost rather than competitive differentiation. Over 60 market leaders have aligned on voluntary APIs and data-sharing protocols under the CMS framework, reducing vendor lock-in risk but also commoditizing basic interoperability functionality.

This regulatory backdrop explains why the market conversation shifted from "should we invest in interoperability" to "which interoperability architecture supports our AI strategy." Compliance is table stakes. The differentiation is in what you can build on top of compliant data pipelines.

What to Watch

The 85% priority increase metric matters less than the direction it indicates. Healthcare organizations are reallocating budget from siloed integration projects to unified data infrastructure. Vendors selling point-to-point integration tools must demonstrate AI-readiness or risk budget reallocation to platforms that bundle both capabilities.

For buyers, the decision framework should focus on three questions: Does this platform reduce time from data ingestion to model deployment? Does it handle the regulatory compliance burden without manual configuration? Can it scale beyond the current AI use case without architectural replacement?

The interoperability problem is not solved—it is redefined. The new requirement is not just moving data between systems, but making that data immediately usable for AI workloads. Vendors that treat interoperability as a feature will lose budget to vendors that treat it as infrastructure.